In addition to being recognized as a chronic inflammatory disease that manifests in the skin, psoriasis is increasingly understood to be a systemic disease that causes immune dysregulation throughout the body. The systemic nature of psoriasis is evidenced by the higher burden of comorbidities and shorter life expectancies of patients with psoriasis, particularly those with early-onset and severe disease. Notably, psoriasis is associated with an increased risk for cardiovascular disease, which is the most common cause of morbidity and mortality in patients with psoriasis. In this review, we examine the association between psoriasis and cardiovascular disease and specifically focus on the role of interleukin 17emediated inflammation as a potential mechanistic link between psoriasis and cardiovascular disease. Moreover, we describe potential treatment approaches to reduce the burden of cardiovascular disease in patients with psoriasis and discuss the clinical importance of the association of these 2 diseases with respect to patient management and education. ( J Am Acad Dermatol 2018;79:345-52.) 
P
soriasis is a common, chronic, inflammatory disease that manifests predominantly in the skin as raised, erythematous, scaly plaques. 1, 2 There is increasing understanding of psoriasis as a systemic inflammatory disease of immune dysregulation that extends beyond the skin. 1, 3 Patients with psoriasis, particularly those with early-onset and severe disease, have a higher burden of comorbidities such as psoriatic arthritis and shorter life expectancies than do those without psoriasis. [4] [5] [6] [7] [8] [9] Notably, psoriasis is associated with increased risk tumor necrosis factor alpha for cardiovascular (CV) disease (CVD), a common cause of morbidity and mortality in psoriasis, and CV risk factors. [10] [11] [12] [13] [14] [15] Further, studies of subclinical atherosclerosis showed that indicators of early disease (eg, higher carotid intima-media thickness, greater coronary artery calcification, higher arterial stiffness, and endothelial dysfunction) were independently and consistently associated with psoriasis even before a CV event occurred. 16 Importantly, improvement in psoriasis severity is associated with reductions in vascular inflammation. 17 The pathophysiology of psoriasis involves inflammatory mediators such as tumor necrosis factor-a (TNF-a), interferon-a and interferon gamma (IFN-g), interleukin (IL) 1b, IL-6, IL-12, IL-17A, IL-17F, IL-22, and IL-23 from various immune cells, primarily type 1 helper and type 17 helper T (Th17) cells but also keratinocytes, other T cells, and dendritic cells. 1, 2, 18 Inflammation also plays a key role in atherosclerosis, the hallmark of CVD. 19, 20 Psoriasis and CVDs such as atherosclerosis share common pathogenic features, including local and systemic immunologic processes, inflammatory cytokine/chemokine profiles, and inflammatory markers (Fig 1) . [18] [19] [20] Further, there is an association between psoriasis and obesity, and adipokines promote metabolic syndrome and CVDs. [21] [22] [23] Understanding the immune-mediated mechanisms that these disorders share is critical to optimal psoriasis management. Although there is evidence that other factors such as the TNF-a pathway are also involved in the pathogenesis of both psoriasis and CVD, we choose to focus on evidence relating to the association between IL-17 and CVD for this review. Herein, we discuss the role of IL-17emediated inflammation as a potential mechanistic link between psoriasis and CVD, hypothesize potential treatment approaches to reduce the burden of CVD in psoriasis, and discuss the clinical importance of these findings with respect to patient management and education.
PSORIASIS AND CV RISK
Psoriasis is associated with numerous CVDs and associated risk factors, and it confers an approximately 25% increase in relative risk for CVD, independent of smoking, obesity, and hyperlipidemia. 14, 16, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Additionally, patients with severe psoriasis have an additional 6.2% absolute risk for major adverse cardiac events over 10 years relative to the general population. 12 Patients with psoriasis have poorer CVD-related prognoses. For instance, in patients with a first-time myocardial infarction (MI), the composite rate of recurrent MI, stroke, and CV death was significantly higher among patients with psoriasis than among those without psoriasis. 44 In a systematic review and meta-analysis, risk for CV death was greater with severe psoriasis (rate ratio, 1.39; 95% confidence interval, 1.11-1.74) than with mild psoriasis (rate ratio, 1.03; 95% confidence interval, 0.86-1.25). 13 In these and other studies, risk for allcause mortality and CV mortality was greater for severe psoriasis than for mild or no psoriasis. 7, 8, 13, 30, 44 CV risk increases with psoriasis severity, and this association is independent of traditional CV risk factors in some studies. 10, 13, 29, 32, 35, 38, 41, 43, [45] [46] [47] [48] [49] [50] [51] For example, psoriasis severity is associated with increased vascular inflammation independent of traditional CV risk factors. 50 Additionally, psoriasis severity is significantly associated with coronary calcium score. 52 Evidence also indicates that risk for CVD correlates with duration of psoriasis. 24, 53 Further, risk for CVD increases as the number of psoriasis-affected body sitesda potential severity predictordrises. 46 Not all investigations, however, support a link between psoriasis and CVD and/or associated risk factors, [54] [55] [56] [57] [58] possibly because of variability in psoriasis severity or other patient characteristics (eg, disease duration, affected body sites, and patient age), classification of predictors and outcomes, or use of appropriate CVD or risk factor treatments.
INFLAMMATORY MECHANISMS THAT MEDIATE DISEASE PATHOLOGY OVERLAP BETWEEN PSORIASIS AND CVD
Though the pathogenesis of psoriasis is not fully understood, the contributions of critical T-cell subsets and effector cytokines that mediate underlying chronic inflammation are well defined.
1,2 In particular, evidence demonstrates the role of IL-17A, a cytokine produced primarily by Th17 cells that is involved in activation and proliferation of keratinocytes, which ultimately leads to amplification of proinflammatory signals in the skin (Fig 1) . 1, 18, 20 Blockade of IL-17A or its receptor reverses clinical,
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Psoriasis is associated with various comorbidities, including cardiovascular disease. histologic, and molecular features of psoriasis. [59] [60] [61] Further, medications such as secukinumab and ixekizumab, which selectively target IL-17A, are efficacious in moderate-to-severe plaque psoriasis. [62] [63] [64] Inflammatory processes have also been implicated in CVD pathogenesis (Fig 1) . Many key inflammatory cell types and mediators overlap with those involved in the development of psoriasis (eg, Th17 cells and IL-17A), indicating shared pathogenic mechanisms between these diseases. 1, 2, 11, [18] [19] [20] 65, 66 The presence of systemic inflammation in psoriasis has been demonstrated at the whole-body level by the sensitive imaging technique fludeoxyglucose F 18 positron emission tomography/computed tomography (FDG-PET/CT). 67 Systemic inflammation was detected in focal areas of skin and in the vasculature, joints, and visceral tissues of patients with moderateto-severe psoriasis (defined as[10% of body surface area affected in this trial). Additionally, levels of vascular inflammation in the aorta were significantly higher in patients with psoriasis than in age-and sex-matched controls, even after adjustment for traditional CVD risk factors. Accumulating evidence supports a role for IL-17A, specifically, in the inflammatory events that lead to atherosclerotic disease, and parallels have been drawn between the pathogenesis of psoriatic and atherosclerotic plaques (Fig 1) . 19, 20 Interestingly, IL-17 has both proatherogenic and protective CV effects. 68 Patients with psoriasis have increased numbers of Th17 cells within the circulation and in psoriatic plaques and increased levels of IL-17A messenger RNA and protein in psoriatic plaques. 18 Likewise, patients with acute coronary syndrome have increased numbers of circulating Th17 cells and associated cytokines, including IL-17A. 69 In a study using blood samples and evaluation of coronary arteries from patients with symptomatic coronary atherosclerosis or outpatients of similar age, sex, and race without cardiac disease, IL-17A and IFN-g were produced concomitantly and acted synergistically to elicit inflammatory responses in vascular smooth muscle cells. 70 Further, hyperlipidemia induced IL-17A production and subsequent activation of human aortic endothelial cells and increased monocyte adhesion in vitro. 71 Additional support for IL-17A as a common inflammatory mediator in psoriasis and CVD comes from human and animal studies of myocardial ischemia-reperfusion injury, unstable angina, acute MI, and atrial fibrillation. Plasma levels of IL-17A are elevated in unstable angina or acute MI, and these levels directly correlate with the degree of platelet aggregation measured in vitro, 72 suggesting that IL-17A may promote platelet aggregation in patients with acute coronary syndrome. IL-17A is upregulated during experimental myocardial ischemia-reperfusion and promotes vascular remodeling by recruiting neutrophils and triggering apoptosis of cardiomyocytes in animal models. [73] [74] [75] Furthermore, blockade of IL-17A ameliorates ischemia-reperfusion injury and reduces levels of proapoptotic markers of ischemia-reperfusion injury. 74 Levels of IL-17F (a less potent isoform of IL-17 that can form heterodimers with IL-17A) 76 and the IL-17 receptor are also increased, suggesting that IL-17 signaling may play a fundamental role in postinfarct inflammatory and apoptotic responses. 74 IL-17A levels also are elevated in a model of atrial fibrillation; neutralization of endogenous IL-17A suppresses inflammation, decreases incidence and duration of atrial fibrillation episodes, and reduces the probability of development of atrial fibrillation. 77 In other models, inhibition of IL-17A or genetic deficiency of IL-17A or its receptor is associated with significantly smaller atherosclerotic lesions. 78, 79 Lastly, IL-17Aemediated inflammation originating in skin has systemic effects on the vasculature in mice with a psoriasis-like phenotype. 80 Overexpression of IL-17A in keratinocytes triggers severe psoriasis-like skin inflammation, causing increased numbers of circulating inflammatory cells and vascular reactive oxidative species, induces severe endothelial dysfunction, increases systolic blood pressure, produces left ventricular hypertrophy, and increases mortality. Blocking TNF-a and IL-6, which act downstream of IL-17A, results in improvements in skin lesions and partial vascular improvements. 80 
IS THERE A ROLE FOR IL-17A INHIBITORS IN CVD RISK MANAGEMENT OF PSORIASIS?
In atherosclerosis mouse models, IL-17A is proatherogenic, inducing inflammatory cell migration and cytokine/chemokine production. 78, 81, 82 Additionally, functional blockade of IL-17A reduces lesion development, apoptosis in plaques, plaque vulnerability, inflammatory cellular infiltration, inflammatory cytokine/chemokine expression, and tissue activation. 78, [81] [82] [83] [84] The role of IL-17 in CVD is proposed to be context dependent; factors affecting the actions of IL-17A include the cell type producing it and the cytokine profile of the local microenvironment. 85 For example, concomitant increase in IL-17 and IL-10 levels and reduction in IFN-g likely limits lesion development and promotes plaque stability, whereas simultaneous production of IL-17 and IFN-g likely promotes lesion progression and plaque instability. 85 These findings raise important questions about the role of IL-17 in atherogenesis that need to be addressed in prospective, randomized trials.
Treatment of underlying inflammation in psoriasis is hypothesized to reduce CVD risk. This theory is supported by data on psoriasis therapies that have anti-inflammatory effects upstream of IL-17A, including methotrexate and TNF inhibitors. [86] [87] [88] [89] Results of smaller, prospective, observational studies provide additional support that systemic antiinflammatory treatment of psoriasis and inflammatory conditions reduces risk for CVD via effects on associated risk factors. 66, [90] [91] [92] Systemic anti-inflammatory treatments to reduce risk for CVD or prevent recurrent CV events in psoriasis are being evaluated in prospective randomized controlled trials, including the Cardiovascular Inflammation Reduction Trial (NCT02576067), wherein CV morbidity and mortality among patients who had a prior MI or angiographically demonstrated multivessel coronary artery disease and are receiving low-dose methotrexate are being evaluated, and the Canakinumab Anti-inflammatory Thrombosis Outcome Study (NCT01327846), in which effects of antieIL-1b (canakinumab) therapy following MI are under investigation.
IL-17A inhibitors are a new class of antiinflammatory agents, and data evaluating their effect on CVD risk are limited. The effects of the IL-17A inhibitor secukinumab on vascular inflammation and CV risk in patients with psoriasis are being evaluated in a prospective vascular inflammation trial (Vascular Inflammation in PsoriasisSecukinumab; NCT02690701). On the basis of overlapping inflammatory profiles, it would be reasonable to investigate whether IL-17 inhibitors may confer CV benefits in psoriasis. A pooled safety analysis of 3430 patients who received secukinumab (representing 2725 patient-years [PYs] of exposure) supports this theory. 93 In patients with moderate-tosevere psoriasis, the exposure-adjusted incidence of an adjudicated major adverse cardiac event over 52 weeks was similar between secukinumab, 300 mg (0.42/100 PYs); secukinumab, 150 mg (0.35/100 PYs); and etanercept (0.34/100 PYs), despite more CVD risk factors at baseline in patients receiving secukinumab. 93 A registry study of acute MI suggests that caution is warranted when investigating IL-17 inhibition in CVD; serum levels of IL-17 below the median (6.26 pg/mL) were significantly associated with higher risk for all-cause mortality and recurrent MI at 2 years, even after adjustment for known CV risk factors, C-reactive protein levels, and treatments (including statins). 94 A possible explanation for these disparate findings may be differences in the local cytokine microenvironment at the location of an atherosclerotic plaque between patients with and without psoriasis.
Most evidence linking anti-inflammatory therapy with reductions in CVD risk is limited by use of surrogate markers (eg, levels of C-reactive protein, measures of insulin sensitivity, lipids, or endothelial markers) to assess changes in CV risk. Use of imaging should complement findings obtained by using surrogate markers. In ongoing large, prospective, randomized trials, the effects of various biologic antiinflammatory therapiesdincluding adalimumab Initial findings of studies evaluating the effects of biologic therapy on vascular inflammation are mixed. In a small study of patients receiving ustekiumab who achieved a 75% improvement on the Psoriasis Area and Severity Index, inflammation of the liver, spleen, and aorta was significantly decreased compared with that in age-, sex-, and body mass indexematched controls. 95 However, a trial of adalimumab did not show benefit compared with placebo in reducing vascular inflammation after 16 weeks. 96 Collective data should provide a strong evidence base for modification of CVD risk in psoriasis; however, variations in long-term CVD outcomes such as MI, stroke, and mortality also should be assessed in future trials to provide the best evidence supporting use of anti-inflammatory therapies for CVD risk reduction.
CLINICAL IMPORTANCE OF RECOGNIZING CVD RISK IN PSORIASIS
An important step toward optimal patient management and reduction of the overall burden of CVD in psoriasis is to educate dermatologists about the benefits of appropriate screening and referral for CV risk factors. 97 According to guidelines, patients with psoriasis should be screened for traditional, modifiable CV risk factors and managed appropriately to reduce risk. 98, 99 However, patients with psoriasis are not screened for CVD risk factors at most outpatient visits. Primary care practitioners can play an important role in screening patients with psoriasis for CV risk factors, and dermatologists should encourage patients to ask for such screenings. We recommend that screening for CVD risk factors be performed by primary care physicians.
CONCLUSIONS
Psoriasis is a multisystem, inflammatory condition associated with increased risk for CV comorbidities. A multidisciplinary approach to patient management is therefore required. Many issues surrounding the relationship between psoriasis and CVD (eg, conclusively establishing a dose-dependent association between CV risk and psoriasis severity, psoriatic plaque thickness, and other disease characteristics) are unresolved. Inflammatory mechanisms, including the IL-17A pathway, are potential links between psoriasis and CVD. Although evidence suggests that modifying underlying inflammation in psoriasis may reduce CVD risk, results of ongoing prospective trials assessing anti-inflammatory interventions should provide further evidence and indicate whether these therapies are efficacious. Increasing health care provider and patient awareness of increased risk for CVD associated with psoriasis is important to encourage more widespread screening and referral and, ultimately, to minimize the burden of CVD in psoriasis.
